Prescribing information

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

This selection of resources is designed for healthcare professionals to support patients with relapsing forms of multiple sclerosis (RMS) throughout their KESIMPTA journey.

You can download these materials and share them with your healthcare team. There is a separate tab for resources which can be shared with patients.

Preview image. KESIMPTA Demonstration Pen Kit.
 

KESIMPTA DEMONSTRATION PEN KIT

A self-injection demonstration kit is available to help show patients how to use the injection pen correctly. To obtain a demonstration kit, please contact Novartis directly or get in touch with your local Novartis representative.

Download

Preview image. Patient Discussion Guide.
 

PATIENT DISCUSSION GUIDE

In a presentation format, this guide helps you lead an introductory discussion with your patients who have been prescribed KESIMPTA.

Download

Preview image. GP Letter.
 

GP LETTER

A letter template that can be sent to your patient’s GP explaining the prescription for KESIMPTA and important information on its appropriate use.

Download

 

Preview image. Treatment Initiation Checklist.
 

TREATMENT INITIATION CHECKLIST

A checklist to follow for the initiation of treatment with KESIMPTA, from pre-prescription contraindication checks through to administration of the first dose.

Download

Preview image. Kesimpta Switch Tool.
 

KESIMPTA SWITCH TOOL

The KESIMPTA switch tool provides guidance on how to switch patients to KESIMPTA from other treatments.

View

 

Image thumbnail 'Getting to know KESIMPTA®▼ PATIENT WELCOME BOOKLET
 

PATIENT WELCOME BOOKLET

A useful booklet for patients prescribed KESIMPTA. It explains about how KESIMPTA works, potential side effects, maintaining well-being and includes an injection diary for patients to record their treatment progress.

Download

 
Rate this content: 
Average: 4 (1 vote)
UK | November 2023 | 311916

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com